Clinical trials · New York
Lung Cancer (Diagnosis) clinical trials in New York
We’re tracking 124 recruiting lung cancer (diagnosis) studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07680764RecruitingPhase 2
Imzokitug plus pumitamig and chemo for first-line advanced lung cancer
This trial tests a new combination of drugs (imzokitug, pumitamig, and platinum-doublet chemotherapy) as a first treatment for advanced or metastatic non-small cell lung cancer that has not spread to the brain. The goal is to see if adding imzokitug makes the standard treatment work better.
New York, New YorkAges 18 years+ - NCT05349227Recruiting
After-cancer digital coaching and wearable tracking outcomes study
This study tests a digital health coaching program (using phone/tablet check-ins and wearable data) to understand health and quality-of-life outcomes after cancer treatment. It may help you learn healthy habits and track progress over time.
New York, New YorkAges 18 years+ - NCT07476287RecruitingPhase 2
Study of PF08634404 plus chemo for transformed small cell lung cancer
This trial tests a new study drug (PF08634404) combined with standard chemotherapy for people whose non-small cell lung cancer has changed into a more aggressive form called small cell lung cancer. It hopes to improve outcomes by targeting the cancer in two ways.
Commack, New YorkAges 18 years+ - NCT07323732RecruitingPhase 2
BIO 300 and radiation for lung cancer with lung scarring
This trial tests if adding BIO 300 to chest radiation is safe and helps people who have both non-small cell lung cancer (early stage) and interstitial lung disease (scarring of the lungs). It aims to find better treatment options for this specific group.
East White Plains, New YorkAges 18 years+ - NCT07287085Recruiting
Increasing lung cancer screening in emergency patients
This study tests a program to help emergency department patients get screened for lung cancer. If you smoke or used to smoke, the study will see if a text message reminder can help you schedule a screening test.
Rochester, New YorkAges 50–80 - NCT07216144Enrolling by invitation
Lung cancer screening outreach in at-risk New Yorkers
This study helps patients at Ryan Health who are at risk for lung cancer get a free lung cancer screening (a low-dose CT scan). If you're between 50 and 80, smoke or used to smoke, and haven't had this scan in the past year, you may be able to participate.
New York, New YorkAges 50–80 - NCT07017829RecruitingPhase 2
Combination therapy for STK11-mutant lung cancer
This trial tests a new drug (GT103) combined with the approved immunotherapy drug pembrolizumab for people with advanced lung cancer that has a specific genetic change (STK11). The goal is to see if adding GT103 helps control the cancer better than pembrolizumab alone.
Buffalo, New YorkAges 18 years+ - NCT06869447Recruiting
Better Breathing After Lung Cancer Treatment
This study looks at breathing exercises for people who have finished treatment for early-stage lung cancer. You'll be asked to give a blood sample at home and do breathing training to see if it helps your recovery.
Buffalo, New YorkAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Syracuse, New YorkAges 18 years+ - NCT06122077Recruiting
Blood test for early lung cancer detection in smokers
This trial tests a blood test that looks for multiple signals to find lung cancer early. If you are a smoker or former smoker over 50, this test might help detect cancer before you have symptoms.
Binghamton, New YorkAges 50 years+ - NCT06673329RecruitingPhase 1
Brodalumab for immune-related side effects from cancer treatment
This trial tests if brodalumab, an antibody that blocks a specific immune pathway (IL-17), can help control side effects caused by immunotherapy cancer treatment. It is for people with advanced solid organ cancers who have immune-related side effects that are suspected to involve IL-17.
New York, New YorkAges 18 years+ - NCT06559059Recruiting
Virtual cancer program for Veterans with new cancer
This study looks at how well a virtual (telemedicine) cancer program works for Veterans who are newly diagnosed with lung, prostate, breast, or colon cancer. Participation involves a telemedicine visit at a VA medical center instead of traveling to the hospital.
Brooklyn, New YorkAges 18 years+ - NCT06498635RecruitingPhase 3
Immunotherapy after surgery for lung cancer with no remaining cancer
This trial tests whether giving immunotherapy (durvalumab) after surgery can help prevent lung cancer from coming back if you already had a complete response to chemo and immunotherapy before surgery. It is for people with early-stage non-small cell lung cancer who had no cancer left after treatment.
Buffalo, New YorkAges 18 years+ - NCT06424327Recruiting
Lung cancer surgery registry
This study collects information from people having surgery to remove a small part of the lung (segmentectomy) for early-stage lung cancer. It helps doctors learn more about this surgery and its outcomes.
New York, New YorkAges 18 years+ - NCT06060613RecruitingPhase 1/Phase 2
Engineered immune cells for advanced melanoma or lung cancer
This trial tests a new treatment called OBX-115, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for people with advanced melanoma or non-small cell lung cancer that has not responded to standard treatments.
New York, New YorkAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
New York, New YorkAges 18 years+ - NCT05854563Recruiting
Study using collected cough samples to learn about lung disease
This trial looks at “cough capture” samples to better understand what is happening in the lungs. You might be eligible if you’re having a bronchoscopy for medical reasons and don’t already have lung cancer.
The Bronx, New YorkAges 21 years+ - NCT04063501Recruiting
Study of gut microbes during immunotherapy for lung cancer
This trial studies how gut bacteria (the microbiome) and the body’s immune signs change over time while you receive PD-1–based immunotherapy for advanced, unresectable non–small cell lung cancer. The goal is to learn which immune and microbial patterns might relate to how well treatment works and how patients respond.
New York, New YorkAges 18–100 - NCT05657873RecruitingPhase 2
Targeted radiation for metastatic lung cancer with liver spread
This trial studies whether adding targeted radiation to the liver (small-area, high-precision radiation) can help people with stage IV non-small cell lung cancer. Participants also start standard “anti–PD-1/PD-L1” immunotherapy (with chemotherapy in some cases).
Rockville Centre, New YorkAges 18 years+ - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Staten Island, New YorkAges 18 years+ - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
New York, New YorkAges 18–80 - NCT05419076RecruitingPhase 2
SRS radiation for small cell lung cancer with brain spread
This Phase 2 trial tests a type of focused radiation (stereotactic radiosurgery, or SRS) for people with small cell lung cancer that has spread to the brain. It looks at whether this approach can treat brain metastases when the cancer has limited to a certain number of spots.
Commack, New YorkAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Elmhurst, New YorkAges 40–75 - NCT04991025RecruitingPhase 2
Adding certolizumab to chemotherapy and nivolumab for lung cancer
This study tests whether adding an extra medication, certolizumab, to the usual chemotherapy and an immunotherapy drug called nivolumab can help people with early-stage lung cancer before they have surgery. It aims to see if this combination shrinks the cancer more and improves outcomes.
Commack, New YorkAges 18 years+
Where these studies are running in New York
Institutions with a site for the recruiting lung cancer (diagnosis) studies listed above.
- Memorial Sloan Kettering Cancer Center · 9 studies
- Memorial Sloan Kettering Nassau · 7 studies
- Memorial Sloan Kettering Westchester · 6 studies
- Memorial Sloan Kettering Commack · 4 studies
- Roswell Park Comprehensive Cancer Center · 3 studies
- Columbia University Irving Medical Center · 2 studies
- Glens Falls Hospital · 2 studies
- Montefiore Medical Center · 2 studies
What taking part in a lung cancer (diagnosis) study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Lung Cancer (Diagnosis) trials in other states
Common questions
- Are there lung cancer (diagnosis) clinical trials in New York?
- Yes. We're currently tracking 124 recruiting lung cancer (diagnosis) studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lung cancer (diagnosis) study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lung cancer (diagnosis) trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lung cancer (diagnosis) studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.